In the open-label extension of ATTRibute-CM (389 enrolled), continuous acoramidis versus switching from placebo at month 30 reduced all-cause death (HR 0.55) and cardiovascular death (HR 0.51) through month 54 in transthyretin amyloid cardiomyopathy; no new safety concerns.
RCTn = 389
Soman et al. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial